Supplemental NDA for stronger version of Advair deemed "not approvable"

A GlaxoSmithKline supplemental NDA for a stronger version of asthma drug Advair Diskus for use in treating patients with chronic obstructive pulmonary disease, recommended for approval by an FDA advisory committee, has been deemed “not approvable” in another apparent show of agency independence from its outside panels.


Next Article in Legal/Regulatory